FGFR3 and non-small cell lung carcinoma: Here, we report a case of a patient with <i>FGFR3-TACC3</i> fusion squamous NSCLC who achieved a radiographic response and disease control for 11 months on initial treatment with erdafitinib and subsequently obtained an additional 8 months of disease control after erdafitinib retreatment after 5 months of intervening chemotherapy.